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These recommendations from the ISSHP are based upon available literature and expert 
opinion. It is intended that this be a ‘living’ document, to be updated when needed as more 
research becomes available to influence good clinical practice. Unfortunately there is a 
relative lack of high quality randomised trials in the field of Hypertension in Pregnancy 
compared with studies in essential hypertension outside of pregnancy and ISSHP 
encourages greater funding and uptake of collaborative research in this field. Accordingly, 
the quality of evidence for the recommendations in this document has not been graded, 
though relevant references and explanations are provided for each recommendation. The 
document will be a ‘living’ guideline and we hope to be able to grade recommendations in 
the future. 
 
Guidelines and recommendations for management of hypertension in pregnancy are 
typically written for implementation in an ideal setting. It is acknowledged that in many 
parts of the world, it will not be possible to adopt all of these recommendations; for this 
reason, options for management in less-resourced settings are discussed separately in 
relation to diagnosis, evaluation, and treatment.  
 
This document has been endorsed by the International Society of Obstetric Medicine (ISOM) 
and the Japanese Society for the Study of Hypertension in Pregnancy (JSSHP). 
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KEY POINTS: 
All units managing hypertensive pregnant women should maintain and review uniform 
departmental management protocols and conduct regular audits of maternal & fetal 
outcomes. 
 
The cause(s) of pre-eclampsia and the optimal clinical management of the hypertensive 
disorders of pregnancy remain uncertain; therefore, we recommend that every 
hypertensive pregnant woman be offered an opportunity to participate in research, 
clinical trials and follow-up studies. 
 
Classification 
1. Hypertension in pregnancy may be chronic (pre-dating pregnancy or diagnosed 
before 20 weeks of pregnancy) or de novo (either pre-eclampsia or gestational 
hypertension). 
 
2. Chronic hypertension is associated with adverse maternal and fetal outcomes and is 
best managed by tightly controlling maternal blood pressure (BP 110-140/85 
mmHg), monitoring fetal growth and repeatedly assessing for the development of 
pre-eclampsia and maternal complications. This can be done in an outpatient setting. 
 
3. White-coat hypertension refers to elevated office/ clinic (≥140/90mmHg) blood 
pressure but normal blood pressure measured at home or work (<135/85mmHg); it 
is not an entirely benign condition and conveys an increased risk for pre-eclampsia.  
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4. Masked hypertension is another form of hypertension, more difficult to diagnose, 
characterised by blood pressure that is normal at a clinic or office visit but elevated 
at other times, most typically diagnosed by 24 hour ambulatory BP monitoring 
(ABPM) or automated home blood pressure monitoring (HBPM). 
 
5. Gestational hypertension is hypertension arising de novo after 20 weeks’ gestation in 
the absence of proteinuria and without biochemical or haematological 
abnormalities. It is usually not accompanied by fetal growth restriction. Outcomes in 
pregnancies complicated by gestational hypertension are normally good, but about a 
quarter of women with gestational hypertension (particularly those who present at 
<34 weeks) will progress to pre-eclampsia and have poorer outcomes.   
 
6. Pre-eclampsia is a complex medical disorder; world-wide, each year, it is responsible 
for over 500,000 fetal and neonatal deaths and over 70,000 maternal deaths. Pre-
eclampsia can deteriorate rapidly and without warning; we do not recommend 
classifying it as ‘mild’ or ‘severe’.  
 
7. Proteinuria is not mandatory for a diagnosis of pre-eclampsia. Rather, this is 
diagnosed by the presence of de novo hypertension after 20 weeks’ gestation 
accompanied by proteinuria and/or evidence of maternal acute kidney injury, liver 
dysfunction, neurological features, hemolysis or thrombocytopenia, and/or fetal 
growth restriction. Pre-eclampsia may develop or be recognised for the first time 
intra-partum or early post-partum in some cases. 
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8. The HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low platelets) is one 
(serious) manifestation of pre-eclampsia and not a separate disorder. 
 
Diagnosis of hypertension and proteinuria 
9. Home blood pressure monitoring is a useful adjunct in the management of chronic 
hypertension and is mandatory in the management of white-coat hypertension. 
 
10. Proteinuria is optimally assessed by screening with automated dipstick urinalysis and 
then if positive quantifying with a urine protein/creatinine ratio. A ratio 
>30mg/mmol (0.3mg/mg) is abnormal.  
 
Prediction and prevention of pre-eclampsia and associated complications 
11. No first or second trimester test or set of tests can reliably predict the development 
of all cases of pre-eclampsia; however, a combination of maternal risk factors, blood 
pressure, Placental Growth Factor (PlGF) and uterine artery Doppler can select 
women who may benefit from 150 mg/day of aspirin to prevent pre-term (before 37 
weeks gestation) but not term pre-eclampsia. ISSHP supports first trimester 
screening for risk of pre-eclampsia when this can be integrated into the local health 
system, although the cost effectiveness of this approach remains to be established.  
 
12. ISSHP recommends that women with established strong clinical risk factors for pre-
eclampsia (i.e., prior pre-eclampsia, chronic hypertension, pre-gestational diabetes, 
maternal BMI >30kg/m2, antiphospholipid syndrome and receipt of assisted 
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reproduction) be treated, ideally before 16 weeks but definitely before 20 weeks, 
with low dose aspirin (defined as 75-162 mg/day, as studied in RCTs).  
 
13. We recommend at this stage against the routine clinical use of ‘rule-in’ or ‘rule-out’ 
tests (specifically PlGF or sFLT-1/PlGF ratio) for pre-eclampsia, which should continue 
to be evaluated within the context of clinical trials. 
 
14. Women considered at increased risk for pre-eclampsia as above should receive 
supplemental calcium (1.2 to 2.5 g/day) if their intake is likely to be low 
(<600mg/day), in addition to aspirin. When intake cannot be assessed or predicted it 
is reasonable to give calcium. 
 
15. Low molecular weight heparin is not indicated to prevent pre-eclampsia, even with a 
history of prior early onset pre-eclampsia. 
 
16. Women should exercise during pregnancy to maintain health, appropriate body 
weight and reduce the likelihood of hypertension. 
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Management 
17. Regardless of the hypertensive disorder of pregnancy, blood pressure requires 
urgent treatment in a monitored setting when severe (> 160/110 mmHg); acceptable 
agents for this include oral nifedipine or intravenous labetalol or hydralazine. Oral 
labetalol may be used if these treatments are unavailable. 
 
18. Regardless of the hypertensive disorder of pregnancy, blood pressures consistently 
at or above 140/90 mmHg in clinic or office (or >135/85mmHg at home) should be 
treated, aiming for a target diastolic blood pressure of 85 mmHg in the office (and 
systolic blood pressure of 110-140 mmHg) to reduce the likelihood of developing 
severe maternal hypertension and other complications such as low platelets and 
elevated liver enzymes with symptoms. Antihypertensive drugs should be reduced or 
ceased if diastolic BP falls below 80mmHg.  Acceptable agents include oral 
methyldopa, labetalol, oxprenolol, nifedipine, and 2nd or 3rd line agents include 
hydralazine and prazosin. 
 
19. Women with pre-eclampsia should be assessed in hospital when first diagnosed; 
thereafter, some may be managed as outpatients once it is established that their 
condition is stable and they can be relied upon to report problems and monitor their 
blood pressure. 
 
20. Women with pre-eclampsia who have proteinuria and severe hypertension, or 
hypertension with neurological signs or symptoms, should receive magnesium 
sulphate (MgSO4) for convulsion prophylaxis. 
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21. Fetal monitoring in pre-eclampsia should include an initial assessment to confirm 
fetal well-being. In the presence of fetal growth restriction, a recommended 
schedule for serial fetal surveillance with ultrasound is detailed within these 
recommendations.  
 
22. Maternal monitoring in pre-eclampsia should include: blood pressure monitoring, 
repeated assessments for proteinuria if it is not already present, clinical assessment 
including clonus, and a minimum of twice-weekly blood tests for hemoglobin, 
platelet count, and tests of liver and renal function, including uric acid, the latter 
being associated with worse maternal and fetal outcomes. 
 
23. Women with pre-eclampsia should be delivered if they have reached 37 weeks’ (and 
zero days) gestation or if they develop any of the following:  
 
a. repeated episodes of severe hypertension despite maintenance treatment 
with three classes of antihypertensive agents;  
b. progressive thrombocytopenia;  
c. progressively abnormal renal or liver enzyme tests;  
d. pulmonary oedema;  
e. abnormal neurological features such as severe intractable headache, 
repeated visual scotomata, or convulsions;  
f. Non-reassuring fetal status. 
 
11 
 
Postpartum care 
24. In the early post-partum period, women with pre-eclampsia should be considered at 
high risk for pre-eclamptic complications for at least 3 days and should have their BP 
and clinical condition monitored at least every four hours while awake. 
Antihypertensives administered antenatally should be continued, and consideration 
should be given to treating any hypertension before day six postpartum with 
antihypertensive therapy. Thereafter, antihypertensive therapy may be withdrawn 
slowly over days, but not ceased abruptly. It is important to note that eclamptic 
seizures may develop for the first time in the early post-partum period. 
 
25. Non-steroidal anti-inflammatory drugs (NSAIDs) for postpartum analgesia should be 
avoided in women with pre-eclampsia unless other analgesics are not working; this is 
especially important if they have known renal disease, or pre-eclampsia is associated 
with placental abruption, acute kidney injury (AKI), or other known risk factors for 
AKI (e.g., sepsis, post-partum hemorrhage). 
 
26. All women should be reviewed at 3 months post-partum to ensure that BP, 
urinalysis, and any laboratory abnormalities have normalised. If proteinuria or 
hypertension persists then appropriate referral for further investigations should be 
initiated. 
 
27. There are significant long-term cardiovascular risks for women with chronic 
hypertension and those who have had gestational hypertension or pre-eclampsia. 
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One initial recommendation may be to aim to achieve pre-pregnancy weight over 12 
months and to limit inter-pregnancy weight gain through healthy lifestyle.  
 
28. Annual medical review is advised life-long and all such women should adopt a 
healthy lifestyle that includes exercise, eating well and aiming for ideal body weight. 
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Introduction 
World-wide there is disagreement about many aspects of the classification, diagnosis 
and management of the hypertensive disorders of pregnancy. This lack of consensus 
hampers our ability to study not only the immediate rates of adverse maternal and 
fetal outcomes for the various hypertensive disorders in pregnancy, particularly pre-
eclampsia, but also the long term health outcomes of women and babies who survive 
this condition. It also impacts upon research into the pathophysiology of this 
condition and has almost certainly delayed the development of effective screening 
tests and treatments, leading to poorer pregnancy outcomes.  
One scholarly review of available guidelines has shown broad agreement in the 
following areas(1): 
1. Definitions of hypertension, proteinuria, chronic hypertension and gestational 
hypertension; 
2. Prevention of pre-eclampsia with low dose aspirin & supplemental calcium (if 
low calcium intake); 
3. Treatment of severe hypertension; 
4. Use of  MgSO4 for eclampsia & ‘severe’ pre-eclampsia; 
5. Use of antenatal corticosteroids to enhance fetal lung maturity at <34 weeks’ 
gestation if delivery is likely within the next 7 days; 
6. Delivery for pre-eclampsia at term; and 
7. Oxytocin in the third stage of labour. 
 
However, in this analysis there was little or no agreement on: 
1. The definition of pre-eclampsia and ‘severe’ pre-eclampsia; 
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2. Target blood pressure when hypertension is not severe; 
3. Timing of delivery for women with chronic hypertension, gestational 
hypertension, or preterm pre-eclampsia; 
4. Use of  MgSO4 for pre-eclampsia that is not ‘severe’; and 
5. Post-partum maternal monitoring. 
 
Following the 2016 World Congress of the International Society for the Study of 
Hypertension in Pregnancy (ISSHP), it was agreed that a single up-to-date guideline 
should be available that reflects current evidence, and both the collective expertise 
of the ISSHP membership and the leadership role that ISSHP would like to take in 
improving hypertension-related outcomes in pregnancy. Following the Congress, 
ISSHP charged a small group of clinician researchers to update the last statements 
from ISSHP 2013 and 2014 (2, 3).  
 
This guideline provides practical advice on classification, diagnostic criteria and 
management for all clinicians, everywhere, who are involved in the management of 
women with hypertension in pregnancy.  
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SECTION 1. CLASSIFICATION of the HYPERTENSIVE DISORDERS OF PREGNANCY 
The recommended classification for hypertensive disorders of pregnancy is as 
follows: 
Hypertension known before pregnancy or present in the first 20 weeks: 
1. Chronic hypertension 
a. Essential 
b. Secondary 
2. White-coat hypertension 
3. Masked Hypertension 
 
Hypertension arising de novo at or after 20 weeks: 
1. Transient gestational hypertension 
2. Gestational hypertension  
3. Pre-eclampsia* – de novo or superimposed on chronic hypertension 
 
*The term ‘severe pre-eclampsia’ should not be used in clinical practice 
 
Notes: 
 Pre-eclampsia, transient gestational hypertension and gestational 
hypertension are characterised by the new onset of hypertension (blood 
pressure > 140 mmHg systolic or > 90 mmHg diastolic) at or after 20 weeks’ 
gestation(4); as such, it is important to have normal blood pressure 
documented either pre-pregnancy or in early pregnancy before there has 
been much pregnancy-related decrease in blood pressure.  Otherwise, a blood 
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pressure first measured after 12 weeks’ gestation that is normal may reflect 
the usual fall in BP from baseline that occurs by the end of the first trimester; 
in which case there may still be underlying chronic hypertension that has 
been masked by this first trimester BP fall.  
 
 Transient gestational hypertension is hypertension that arises in the 2nd or 3rd 
trimester. The hypertension is usually detected in the clinic but then settles 
with repeated BP readings, such as those taken over the course of several 
hours in a Day Assessment Unit. This differs from white-coat hypertension 
that, by definition, must be present from early pregnancy. Transient 
gestational hypertension is associated with a 40% risk of developing true 
gestational hypertension or pre-eclampsia in the remainder of the pregnancy 
(5), a fact that highlights the importance of carefully following-up such 
women. 
 
 When a woman presents with hypertension in pregnancy at or after 20 weeks’ 
gestation and the earlier blood pressure is unknown, she should be managed 
in pregnancy as if she has gestational hypertension or pre-eclampsia. 
Appropriate investigations should be done after pregnancy to determine if 
she has underlying chronic hypertension. This will generally be apparent 
because the blood pressure will not have normalised within 3 months post-
partum. 
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 Masked hypertension is another form of hypertension, characterised by blood 
pressure that is normal at a clinic or office visit but elevated at other times, 
most typically diagnosed by 24 hour ambulatory BP monitoring (ABPM) or 
automated home blood pressure monitoring (HBPM). Such a diagnosis is 
generally sought when a patient has unexplained abnormalities consistent 
with target organ damage from hypertension but no apparent hypertension. 
Whilst this is a form of chronic hypertension, the prevalence of masked 
hypertension and its significance in pregnancy are less well-studied; for now, 
we don’t recommend seeking this diagnosis in the absence of the above 
features (i.e., unexplained chronic kidney disease, left ventricular hypertrophy 
or retinopathy recognised early in pregnancy). 
 
 Although ISSHP has formerly published a statement documenting ‘severe pre-
eclampsia’, we agree with the position of ACOG and others that pre-eclampsia 
may become a major threat to mother and baby at any stage and 
classification into ‘mild’ or ‘severe’ disease can be erroneous or misleading to 
less experienced clinicians. ACOG has eliminated the diagnosis of ‘severe pre-
eclampsia’ and instead discusses ‘Pre-eclampsia with or without severe 
features’, a sensible clinical approach. 
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SECTION 2.  DIAGNOSIS of the HYPERTENSIVE DISORDERS OF PREGNANCY 
 What constitutes hypertension in pregnancy?  
Hypertension   
 Defined as systolic BP  > 140 and/or diastolic BP >90 mmHg 
 Blood pressure should be repeated to confirm true hypertension  
o if blood pressure is severe (SBP >160 and/or DBP >110 mmHg) 
then the blood pressure should be confirmed within 15 minutes;  
o for less severe blood pressure, repeated readings should be 
taken over a few hours. 
 Use a liquid crystal sphygmomanometer 
o If this is unavailable, use a validated and appropriately calibrated 
automated device 
 
Notes: 
 Mercury sphygmomanometry is no longer available. The best alternative may 
be a liquid-crystal sphygmomanometer(6), but these are not yet widely 
available. Correct cuff size is important, using a ‘large’ cuff if the mid upper 
arm circumference is above 33cm. 
 
 Aneroid devices are used commonly for blood pressure measurement, but 
they may be inaccurate and need to be regularly calibrated. One smaller study 
found that 50% of aneroid devices had at least one BP reading > 10 mmHg out 
compared to the same error in only 10% of mercury devices (7).  
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 Use of an automated device is preferable to use of an aneroid device if the 
automated device has been shown to be reliable in both pregnancy and pre-
eclampsia specifically (8, 9); some devices may be accurate for women with 
chronic or gestational hypertension in pregnancy but not for women with pre-
eclampsia (10).  A list of generally validated home BP monitors, not specific 
for pregnancy, is available at: http://bhsoc.org/bp-monitors/bp-monitors/. 
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What constitutes abnormal Proteinuria in pregnancy?  
 Proteinuria should be assessed initially by automated dipstick urinalysis 
when possible; if not available, careful visual dipstick urinalysis will 
suffice. 
 If positive (> ‘1+’, 30mg/dl) then spot urine protein/creatinine (PCr) 
ratio should be performed 
 A PCr ratio >30mg/mmol (0.3mg/mg) is abnormal 
 A negative dipstick test can usually be accepted and further PCr testing 
is not required at that time.  
 Proteinuria is not required for a diagnosis of pre-eclampsia 
 Massive proteinuria (>5gm/24hours) is associated with more severe 
neonatal outcomes 
 
Notes: 
 The gold standard for diagnosing abnormal proteinuria in pregnancy is a 24-
hour urinary protein ≥300 mg per day, though this is more a time-honoured 
value than one with high scientific proof (11); ideally 24hr creatinine excretion 
will also be used to assess adequacy of collection as without this, the 
estimated daily urine protein excretion is often incorrect(12).  
 
 In practice, the 24hr urine protein measurement will mostly be replaced with 
a spot urine protein/creatinine ratio, a value ≥30 mg per mmol (=0.26 mg/mg, 
usually ‘rounded’ to 0.3 mg/mg) representing significant proteinuria (13-15); 
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this eliminates the inherent difficulties in undertaking 24-hour urine 
collections and speeds up the process of decision-making. 
 
 24hr. urine collection for proteinuria is still indicated to confirm nephrotic 
syndrome which has implications for thromboprophylaxis. 
 
 Dipstick testing is not perfect and a small number of proteinuric cases may be 
missed by a negative dipstick test; a urine PCr below 30mg/mmol also 
occasionally gives a false negative result for abnormal 24hr. proteinuria but in 
such cases the total protein excretion is usually <400mg/day (14). 
 
 At present there is insufficient data to recommend using urinary 
albumin/creatinine ratio but this may change when more research becomes 
available (13, 16), such as the results of DAPPA (Diagnostic Accuracy in Pre-
eclampsia using Proteinuria Assessment, RCTN82607486). 
 
 When neither 24hr nor PCr measures of proteinuria are available, dipstick 
testing provides reasonable assessment of true proteinuria, particularly when 
values are greater than 1 g per litre i.e. 2+ (15, 17).  
 
 There is ongoing debate on the importance of the absolute quantitation of 
proteinuria. Some believe that the degree of proteinuria provides little 
additional risk stratification (except in nephrotic syndrome) and it should not 
be included in considerations of the severity of pre-eclampsia (15, 18-20). 
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Others have shown that massive proteinuria (>5gm/24hours) is associated 
with more severe neonatal outcomes and earlier delivery, and a spot 
Protein/Creat >900 mg/mmol (or >500mg/mmol if age >35) is associated with 
worse maternal outcomes (21, 22). For this reason some units may choose to 
continue measuring proteinuria though it is not recommended that a decision 
to deliver is based upon the degree of proteinuria. 
 
 If proteinuria is diagnosed but subsequent dipstick tests become negative 
then further quantification tests are appropriate to see whether or not true 
proteinuria persists.  
 
 In recent years, gestational proteinuria has been recognised as a real entity.  It 
is unclear exactly how many pregnancies are affected by this condition, 
defined as the new onset of proteinuria in pregnancy without other obvious 
features of pre-eclampsia or primary renal disease.  Women with gestational 
proteinuria have blood levels of placental growth factor that are intermediate 
between those of normal pregnancies and pre-eclampsia, prompting 
consideration that these women have an early form of pre-eclampsia (23). 
The recommended approach to management of these women is to consider 
three possible outcomes.  
1. No features of pre-eclampsia develop throughout pregnancy and 
proteinuria disappears postpartum;  
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2. Proteinuria turns out to be the first feature of pre-eclampsia which is 
defined when the blood pressure subsequently rises or other features of 
pre-eclampsia develop;  
3. The proteinuria persists postpartum and ultimately signifies a primary 
renal disease which has coincidentally developed in the pregnancy, an 
unusual event. 
 
It is therefore recommended to monitor these women more frequently than 
usual for the remainder of their pregnancy, as well as to assess proteinuria at 
3 months postpartum. 
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1. Chronic Hypertension 
 Chronic hypertension refers to high blood pressure predating the 
pregnancy or recognised at <20 weeks’ gestation 
 In practice, this is often diagnosed for the first time at the first or 
early second trimester booking visit 
 Ideally, this ‘office’ or ‘clinic’ hypertension should be confirmed 
by 24 hr. ABPM or HBPM, or at minimum, after repeated 
measurements over hours at the same visit or on two consecutive 
antenatal visits, though this latter approach may not always 
eliminate a diagnosis of ‘white-coat’ hypertension 
 The majority of cases are due to essential hypertension 
 Secondary causes are uncommon 
 ‘White-coat’ hypertension refers to elevated office/ clinic 
(≥140/90mmHg) blood pressure but normal blood pressure 
measured at home or work (<135/85mmHg); it is not an entirely 
benign condition and conveys an increased risk for pre-eclampsia 
(24)  
 
Notes: 
 Many women will not have had their blood pressures measured within 
months before becoming pregnant. In practice therefore, we rely mostly upon 
the first trimester blood pressure to define normal or high blood pressure.   
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 Up to one in four patients with elevated clinic or office blood pressure have 
‘white coat’ hypertension. This diagnosis can be avoided in large part by 
having clinic or office blood pressures recorded by a nurse, rather than a 
doctor, preferably using repeated blood pressure readings (25). We 
recommend that all women have either HBPM monitoring or 24hr ABPM 
before a diagnosis of true essential hypertension is accepted. 
 Normal values for 24 hr. ABPM in pregnancy have been determined (26); 
before 22 weeks, blood pressure values should be below: 24 hr. average 
126/76 mmHg; awake average BP 132/79 mmHg; sleep average BP 114/66 
mmHg. These values are slightly lower than those used as thresholds for 
diagnosing hypertension in non-pregnant women. 
 Most automated home blood pressure devices are accurate in pregnancy, but 
about 25% differ from standard sphygmomanometry devices (27); therefore, 
all women should have their home blood pressure device checked (against a 
calibrated sphygmomanometer or automated device validated for use in 
pregnancy and pre-eclampsia) before using that device. In the absence of 
severe hypertension (>160/110 mmHg), we suggest relying on average BP 
over several days rather than acting upon single readings for women 
monitoring home blood pressure values. 
 Most cases of chronic hypertension are due to essential hypertension, usually 
accompanied by a family history of hypertension and often by overweight or 
obesity.   
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 Secondary causes of hypertension are less common; in the age group of 
women who conceive, the cause is usually an underlying primary renal 
parenchymal disorder (such as reflux nephropathy or glomerulonephritis) and 
less commonly, fibromuscular hyperplasia of the renal arteries or primary 
hyperaldosteronism. ISSHP does not recommend routine testing for any 
secondary cause of hypertension in the absence of clinical clues to these 
conditions. 
ISSHP recommends that all women with chronic hypertension in pregnancy have the 
following tests performed at first diagnosis. This will provide a baseline reference 
should suspicion arise later in pregnancy of superimposed pre-eclampsia (which will 
complicate up to 25% of these pregnancies). 
 A full blood count (haemoglobin and platelet count)  
 Liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), and lactate dehydrogenase (LDH)] and functions tests [international 
normalised ratio (INR), serum bilirubin, and serum albumin] 
 Serum creatinine, electrolytes, and uric acid* 
 Urinalysis & microscopy, as well as PCr or ACR 
o Renal ultrasound if serum creatinine or any of the urine testing are 
abnormal 
*Note: Serum uric acid is not a diagnostic criterion for pre-eclampsia, but 
elevated gestation-corrected uric acid serum levels are associated with worse 
maternal and fetal outcomes (28-30) and should prompt a detailed assessment 
of fetal growth, even in women with gestational hypertension. However, uric 
acid should not be used to determine the timing of delivery.  
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2. Transient Gestational Hypertension  
 
 Transient gestational hypertension is de novo hypertension that 
develops at any gestation that resolves without treatment during 
the pregnancy 
 
Notes: 
 Transient gestational hypertension is not a benign disorder; it is associated 
with approximately 20% chance of developing pre-eclampsia and a further 
20% chance of developing gestational hypertension. Therefore, such women 
should receive extra monitoring throughout their pregnancy, ideally including 
home BP measurements. 
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3. Gestational hypertension (gestational hypertension) 
 Gestational hypertension is persistent de novo hypertension that 
develops at or after 20 weeks’ gestation in the absence of features of 
pre-eclampsia 
 
Notes: 
 Gestational hypertension is not a uniformly benign condition. The risk of 
complications is dependent on the gestational age at which it develops. 
Gestational hypertension is important for two reasons: 
o Pre-eclampsia may develop in 25% of such women, this rate being 
higher the earlier the presentation (31); to date, no tests have reliably 
predicted which women with gestational hypertension will later 
develop pre-eclampsia(32) 
o Gestational hypertension, like pre-eclampsia, is also associated with 
cardiovascular disease in the long-term (33-36). 
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4. Pre-eclampsia  
 Pre-eclampsia is gestational hypertension accompanied by one or more 
of the following new-onset conditions at or after 20 weeks’ gestation: 
1. Proteinuria 
2. Other maternal organ dysfunction, including: 
o Acute kidney injury (AKI) (creatinine > 90umol/L; 1mg/dL)  
o liver involvement (elevated transaminases e.g. ALT or AST >40 
IU/L) with or without right upper quadrant or epigastric 
abdominal pain) 
o neurological complications (examples include eclampsia, altered 
mental status, blindness, stroke, clonus, severe headaches, 
persistent visual scotomata) 
o haematological complications (thrombocytopenia – platelet count 
below 150,000/uL, DIC, hemolysis) 
3. Uteroplacental dysfunction (such as fetal growth restriction, abnormal 
umbilical artery Doppler wave form analysis, or stillbirth) 
 
Notes: 
 Hyperreflexia occurs in many women with pre-eclampsia and resolves post-
partum. However, it is a non-specific finding that is often present in otherwise 
well young women and is highly subject to observer interpretation. Therefore, 
ISSHP no longer recommends including this in the diagnostic criteria. 
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 Headaches in pregnancy are multifactorial. However, in the presence of 
hypertension, a new headache should be considered to be part of pre-
eclampsia until proved otherwise; this is a safe clinical approach. 
 
 Proteinuria is not required for a diagnosis of pre-eclampsia but is present in 
about 75% of cases (19) 
 
 When resources are available, all asymptomatic women with de novo 
hypertension and no dipstick proteinuria should have the following laboratory 
investigations performed to evaluate maternal organ dysfunction. Without 
these, it will be impossible to exclude pre-eclampsia. In some countries, this 
approach will necessitate referral of patients (of whom some will not have 
pre-eclampsia) from smaller units where same-day laboratory facilities are 
not available. Local decision-making strategies will be necessary in these 
areas. 
 
 Hemoglobin, platelet count (and if decreased, tests of coagulation) 
 Serum creatinine 
 Liver enzymes 
 Serum uric acid 
  HELLP: The combination of all or some of haemolysis elevated liver 
enzymes and thrombocytopenia is often referred to as the HELLP 
syndrome. For clinicians familiar with the management of pre-eclampsia, 
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this constellation of abnormalities signifies a more serious part of the 
spectrum of this disorder. However, it is still considered part of pre-
eclampsia and not a separate disorder. ISSHP endorses this approach in 
order to reduce confusion amongst those less familiar with the 
multisystem complications that might occur in pre-eclampsia. In other 
words, women with features of HELLP syndrome should be considered to 
have pre-eclampsia so that all other features of pre-eclampsia will be 
sought and addressed.  
 Controversy remains as to whether fetal growth restriction in the context 
of new onset gestational hypertension, without any other maternal 
feature of pre-eclampsia, should be considered to define pre-eclampsia.  
The authors’ view was that this should apply; given that pre-eclampsia is 
most commonly of itself a primary placental disorder. 
 
 Although it is probable that pre-eclampsia can be present in some cases 
without overt hypertension, ISSHP recommends maintaining new onset 
hypertension in the diagnosis for now. 
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Pre-eclampsia superimposed upon chronic hypertension 
 About 25% of women with chronic hypertension will develop 
superimposed pre-eclampsia. These rates may be higher in women with 
underlying renal disease. 
 This diagnosis is made when a woman with chronic essential 
hypertension develops any of the above maternal organ dysfunction 
consistent with pre-eclampsia.   
 Rises in blood pressure per se are not sufficient to diagnose 
superimposed pre-eclampsia, as such rises are difficult to distinguish 
from the usual increase in blood pressure after 20 weeks’ gestation. 
 In the absence of pre-existing proteinuria, new-onset proteinuria in the 
setting of a rise in blood pressure is sufficient to diagnose superimposed 
pre-eclampsia.  
 In women with proteinuric renal disease, an increase in proteinuria in 
the pregnancy is not sufficient per se to diagnose superimposed PE.  
 Diagnostic biomarkers (particularly PlGF) may assist with diagnosis and 
prognosis in the future but are not yet recommended for this diagnosis. 
 Fetal growth restriction may be part of chronic hypertension per se and 
cannot be used as a diagnostic criterion for superimposed PE.  
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SECTION 3.  PREDICTION AND PREVENTION OF PRE-ECLAMPSIA 
a) Predicting the development of pre-eclampsia  
 No first or second trimester test or set of tests can reliably predict the 
development of all cases of pre-eclampsia; however, a combination of 
maternal risk factors, blood pressure, PlGF and uterine artery Doppler 
can select women who may benefit in particular from 150 mg/day of 
aspirin to prevent pre-term but not term pre-eclampsia (37). ISSHP 
supports first trimester screening for pre-eclampsia when this can be 
integrated into the local health system, although the cost effectiveness 
of this approach remains to be established.  
 
 ISSHP recommends that women with established strong clinical risk factors for 
pre-eclampsia (i.e., prior pre-eclampsia, chronic hypertension, pre-gestational 
diabetes, maternal BMI >30kg/m2, antiphospholipid syndrome and receipt of 
assisted reproduction) be treated, ideally before 16 weeks but definitely before 
20 weeks, with 75-162 mg/day aspirin, as studied in RCTs.  
 
Maternal characteristics and history provide strong clues to which women are 
more at risk of developing pre-eclampsia than others (38), particularly:  
 Prior pre-eclampsia  
 Chronic hypertension 
 Multiple gestation 
 Pre-gestational diabetes 
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 Maternal BMI >30 
 Anti-phospholipid syndrome/SLE 
 Assisted reproduction therapies 
 
It may be possible to narrow the risk profile for pre-eclampsia further using a 
combination of these risk factors, screening of uterine artery Doppler and plasma 
PlGF. This is an issue for the future. 
 
Notes: 
Many clinical, ultrasonographic, and laboratory parameters have been explored 
during early pregnancy as tools for predicting who will later develop pre-eclampsia. 
These include, amongst others: 
 Uterine artery Doppler studies,  
 Measurement of angiogenic factors (such as soluble Endoglin, PlGF, Soluble 
fms-like tyrosine kinase-1 (sFlt-1) and sFLt-1/PlGF ratio) (39) 
 Numerous others, such as ADAM-12, plasma pregnancy-associated plasma 
protein A (PAPP-A), Placental Protein 13 (PP 13), homocysteine, Asymmetric 
dimethylarginine (ADMA), uric acid and leptin, urinary albumin or calcium (40-
44).   
Maternal characteristics that are most strongly associated with an increased 
likelihood of pre-eclampsia include those listed above as well as underlying renal 
disease or multiple pregnancies. 
Other factors less strongly associated with pre-eclampsia include, but are not limited 
to:  
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 Advanced maternal age,(38)  
 Family history of pre-eclampsia (45, 46).  
 Short duration of sexual relationship ( < 6 months) prior to the pregnancy(47, 
48) 
 Primiparity (although pre-eclampsia may occur in subsequent pregnancies 
even in the absence of pre-eclampsia in the first),  
 Primipaternity – both changed paternity (49) and an inter-pregnancy interval 
greater than 5 years  have been associated with an increased risk for pre-
eclampsia(50),  
 Chronic kidney disease 
 Connective tissue diseases 
 Thrombophilias have no clear association with near term pre-eclampsia but 
Factor V Leiden may be a risk factor for the rarer case of very early onset pre-
eclampsia, particularly when associated with severe fetal growth 
restriction(51).  
 
 One large systematic review demonstrated that parity, pre-eclampsia history, 
race, chronic hypertension and conception method had an area under the 
curve (AUC) 0.76 for predicting early onset pre-eclampsia, and that 
discrimination could be improved with specialised tests (52) .The size of the 
difference in AUC varied widely between model comparisons in this study, 
ranging from -0.005 to 0.24 in favour of specialised models. Improvements in 
discrimination were more modest for models predicting any pre-eclampsia 
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and late-onset pre-eclampsia than for models predicting early onset pre-
eclampsia. 
 
 O’Gorman et al (53) found that the detection rates for preterm and term pre- 
eclampsia were inferior using NICE (National Institute for Health and Care 
Excellence) or ACOG clinical criteria alone to first trimester screening using a 
multivariable approach (that included maternal risk factors, blood pressure, 
maternal PAPP-A and PlGF, and uterine artery Doppler). At a screen positive 
rate of 10%, 370 women would have to be screened, and the 37 identified as 
being at high risk of pre-eclampsia treated with 150 mg/day of aspirin to 
prevent one case of pre-term pre-eclampsia. Importantly, the vast majority 
(~80%) of screen positive women did not have strong clinical risk factors for 
pre-eclampsia.  
 
 In the ASPRE study (37) almost 27,000 women were screened, 6% were 
included in final analysis and 48 (about 0.2%) developed pre-term pre-
eclampsia. This type of screening added a predictive benefit for pre-term pre-
eclampsia above that of clinical predictive factors but the cost-effectiveness of 
the approach is not yet known. Also, screening must be undertaken clinically 
in the same way as in ASPRE, although uterine artery Doppler (pulsatility 
index) is not a difficult procedure to learn.  
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 An important finding in the ASPRE trial (37) was confirmation that aspirin at a 
dose of 150mg at night conferred no greater risk to pregnant women (or their 
newborns) than placebo.  
 
 Randomised Controlled Trials of ‘rule in’ and ‘rule out’ tests are needed and 
must include a co-primary non-inferiority outcome of neonatal morbidity 
because of the very real risk of earlier delivery in these women. 
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b) Tests to ‘Rule –out’ pre-eclampsia 
 
No test should be used routinely as a ‘rule out’ test at this stage, though 
PlGF testing may prove useful in selected groups in future studies. Such 
tests should NOT be employed routinely in clinical practice until further 
clinical studies are conducted. 
 
Notes: 
In May 2016, the NICE group published NICE Diagnostics guidance [DG23] 
(https://www.nice.org.uk/guidance/dg23)  recommending that the Elecsys immunoassay for 
the sFlt-1/PlGF ratio, or the Triage PlGF test, be used with standard clinical assessment to 
help rule out proteinuric pre-eclampsia or pre-eclampsia requiring delivery within the next 7 
(for the sFlt-1/PlGF ratio) or 14 days (for Triage PlGF), in women with suspected pre-
eclampsia between 20 and 34+6 weeks’ gestation.  This recommendation was based 
primarily on two multicentre studies of women with a broad definition of suspected pre-
eclampsia at <34+6 weeks’ gestation. The PROGNOSIS study (54) found that a sFlt1/PlGF 
ratio <38 could reliably rule out development of pre-eclampsia for the next 7 days in women 
with a wide range of inclusion criteria; this finding may not be of any clinical advantage in 
centres already established for regular antenatal follow up but may become of use in 
remote or LMIC areas once further research is conducted. The PELICAN study (55) found 
that a Triage PlGF value of <100 pg/ml or the fifth centile of PlGF concentration for 
gestational age gave high sensitivity with good precision for identifying women likely to 
develop pre-eclampsia needing delivery within 14 days of testing, when presenting with 
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suspected pre-eclampsia before 35 weeks’ gestation. PlGF, alone or in combination with 
sFlt-1, was not recommended to rule-in pre-eclampsia. 
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c) Predicting the course of established pre-eclampsia 
There are recent studies aiming to predict clinical outcomes for women when they 
initially present with early features of pre-eclampsia. Measurement of angiogenic 
factors may play a role in this regard in the future but is still at a research stage(56).  
A clinical predictive model, the PIERS model, can predict the likelihood of a 
composite severe adverse maternal outcome using the following variables 
gathered from 0-48 hrs. after admission with pre-eclampsia (57, 58):  
 gestational age,  
 chest pain or dyspnea,  
 oxygen saturation,  
 platelet count,  
 serum creatinine,  
 AST. 
In practice, pulse oximetry is used infrequently and defaults to an oxygen 
saturation of 97% in the risk model when oximetry is not available 
(https://piers.cfri.ca/PIERSCalculatorH.aspx). 
ISSHP recommends this as a useful adjunct in the initial assessment of women 
with pre-eclampsia. 
 
Notes: 
The PREP Collaborative Network published prognostic models that assist predicting  the 
overall risk of women with established pre-eclampsia to experience a complication using 
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logistic regression (PREP-L), and for predicting the time to adverse maternal outcome using 
a survival model (PREP-S) (59). 
The PREP-S model included maternal age, gestation, medical history, systolic blood 
pressure, deep tendon reflexes, urine protein creatinine ratio, platelets, serum alanine 
amino transaminase, urea, creatinine, oxygen saturation and treatment with 
antihypertensives or magnesium sulfate. The PREP-L model included the above except deep 
tendon reflexes, serum alanine amino transaminase and creatinine (available at 
http://stg.pocketapp.co.uk/qmul/#home). 
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d) Prevention 
 Use low dose aspirin (preferably 150mg/day) started before 16 weeks 
of pregnancy for women at increased risk for pre-eclampsia, 
particularly if any of the following conditions exist: 
o previous pre-eclampsia,  
o pre-existing medical conditions (including chronic 
hypertension, underlying renal disease, or pre-gestational 
diabetes mellitus),  
o antiphospholipid antibody syndrome,  
o multiple pregnancy; 
o obesity 
o Assisted reproduction pregnancy 
 In the face of low calcium intake (<600mg/day), use calcium 1.2 to 2.5g 
per day in women at increased risk. 
 Pregnant women should exercise at least 3 days per week for an 
average 50 minutes using a combination of aerobic exercise, strength 
and flexibility training; this has been associated with less weight gain 
and reduced incidence of hypertensive disorders in pregnancy (60, 61); 
there are no significant adverse effects of exercise in pregnancy. 
 
 No treatment to date can prevent pre-eclampsia in all women.  
 
 In women considered to be at increased risk for pre-eclampsia on the basis of 
clinical factors mentioned above, both low dose aspirin and calcium (in the 
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setting of low calcium intake) are recommended for the prevention of pre-
eclampsia(62-64).  
o Aspirin should be given at a dose between 100 and 150 mg per day, 
started preferably before 16 weeks’ gestation, possibly taken at night, 
and continued until delivery; about 70 women need to be treated to 
prevent one case of pre-eclampsia, particularly severe pre-eclampsia.  
Implementation of this practice is associated with improved outcomes 
(65); it is possible that initiating aspirin later than 16 weeks’ gestation 
may also be of benefit (66)  but we recommend earlier 
commencement. Recent analyses question: a) whether aspirin needs 
be started before 16 weeks or still has benefit if started later, b) the 
magnitude of effect (ranging from 50% to only 10% risk reduction) and 
c) what dose is most beneficial, at least 100 mg seeming to be 
required(67-69).  
 
o The ASPRE study has demonstrated that the use of 150mg aspirin at 
night in women deemed to be high risk for preterm pre-eclampsia on 
the basis of screening with maternal factors, Doppler and maternal 
PlGF reduced the incidence of preterm pre-eclampsia from 4.3% to 
1.6% in the aspirin group (37). The clinical role of such screening tests 
remains uncertain, as discussed above.  
 
o Enoxaparin does not offer any preventative advantage above low dose 
aspirin even in women at high risk for pre-eclampsia (70). 
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 Calcium at a dose of at least 1g/d has been shown to reduce the likelihood of 
pre-eclampsia in women with low calcium intake. The CAP trial (71)data will 
be further reported to examine preventative benefits of supplemental 
calcium in women who are calcium replete (following pre-pregnancy and early 
pregnancy replacement of 500mg/d) compared with women who are not 
replete. This may change future recommendations. 
 
 Exercise using an ACOG program guideline (or aerobic exercise for 50 
minutes, three times per week) in one RCT of 765 women has been associated 
with reduced gestational hypertension and pre-eclampsia as well as less 
weight gain and macrosomia (72).  
 
 Supplemental Vitamin C and E are not recommended and may in fact be 
associated with worse pregnancy outcomes(73). 
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Fetal Monitoring and management for the Hypertensive Disorders of Pregnancy 
 Fetal biometry (bi-parietal diameter together with head circumference, 
abdominal circumference, and femur length which are computed to produce an 
estimate of fetal weight), amniotic fluid volume assessment and fetal Doppler 
waveform analysis should be performed at the first diagnosis of pre-eclampsia 
 In confirmed pre-eclampsia or where there is fetal growth restriction serial 
evaluation of fetal growth, amniotic fluid volume and umbilical artery Doppler is 
recommended from 24 weeks’ gestation until birth, with fetal growth evaluated 
no more frequently than at two weekly intervals. Advice should always be sought 
about ultrasound testing from maternal fetal medicine specialists for earlier 
gestation cases. 
 More frequent ultrasound measurements are needed if there is high umbilical 
artery resistance or absent or reversed end diastolic flow; in these cases 
specialised opinion must be sought. 
 Prenatal corticosteroids for fetal lung maturation should be given between 24+0 
and 34+0 weeks gestation, but may be given up until 38+0 weeks in cases of 
elective delivery by Caesarean section; multiple steroid courses are not 
recommended. 
  MgSO4 for fetal neuro-protection should be administered in gestations prior 
to32 weeks. 
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Notes: 
Pre-eclampsia is, at least in part, a disease of placentation/placental dysfunction and the 
fetus is potentially vulnerable to the effects of uteroplacental insufficiency, particularly fetal 
growth restriction and placental abruption.  
 
 In addition to the ideal schedule of a first trimester dating ultrasound and a mid-
trimester anomaly scan, fetal biometry, amniotic fluid volume assessment and fetal 
Doppler waveform analysis should be performed at the first diagnosis of pre-
eclampsia.  
 
 The ideal scanning schedule thereafter is determined by the presence (or absence) 
of fetal growth restriction at the initial assessment and the gestation at diagnosis.  
o The American Congress of Obstetricians and Gynecologists (ACOG) and Royal 
College of Obstetricians and Gynecologists (RCOG) 
(https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg31/) 
agree that the risk of perinatal morbidity and mortality increases once the 
estimated fetal weight (EFW) or the abdominal circumference (AC) <10th 
centile.  
o ACOG considers amniotic fluid an “important diagnostic and prognostic 
parameter in fetuses with IUGR,” whereas the RCOG notes that amniotic fluid 
assessment has “minimal value in diagnosing” growth restriction. Both 
guidelines agree that umbilical artery (UA) Doppler is not a reliable screening 
technique for fetal growth restriction, but is a useful assessment tool once 
fetal growth restriction is diagnosed.  
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o The Society of Obstetricians and Gynecologists of Canada (74) uses an EFW 
<10th centile for diagnosis of small for gestational age and suggests that UA 
and uterine artery Doppler studies in combination with ultrasound of the 
placental morphology is useful to establish a more refined diagnosis of fetal 
growth restriction.  
 
 In confirmed pre-eclampsia, where the maternal condition allows for continuation of 
pregnancy, serial evaluation of fetal growth, amniotic fluid volume and umbilical 
artery Doppler is recommended from 26 weeks’ gestation until birth. 
 
 The fetal biometry should be assessed no more frequently than every 2 weeks.  
 
 Criteria for the diagnosis of fetal growth restriction include an EFW <10th centile on 
ultrasound based on accurate dating. In particular, an EFW <3rd centile and/or 
abnormal UA Doppler, significantly increase the risk of adverse perinatal outcome.  
 
 Once fetal growth restriction is diagnosed, assessment of fetal growth is 
recommended at two weekly intervals. In addition, amniotic fluid volume and 
umbilical artery Doppler assessment should be carried out.  
 
 If the umbilical artery Doppler demonstrates increased resistance (Pulsatility Index 
>95th centile), the sonographic surveillance should be increased to weekly intervals 
or more frequently if deemed necessary by the managing clinician.  
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 If there is absent end-diastolic flow in the umbilical artery (AEDF) prior to 34 weeks’ 
gestation, daily cardiotocograph (CTG) monitoring, twice weekly UA Doppler and 
amniotic fluid volume assessment is recommended. These women should be 
discussed with the team consultant on a daily basis.  
 
 If there is reversed end-diastolic flow in the umbilical artery (REDF) prior to 30 weeks 
gestation, admission to hospital with daily CTG monitoring, three-times weekly UA 
Doppler and amniotic fluid volume assessment is recommended; an opinion from a 
fetal medicine specialist may be sought to determine fetal viability and guide further 
management.  
 
 In cases of AEDF, delivery should be considered no later than 34 weeks gestation. 
Earlier delivery may be indicated in cases of poor interval growth, or a deterioration 
of sonographic variables (Doppler, amniotic fluid).  
 
 In cases of REDF, delivery should be considered no later than 30 weeks gestation. 
Earlier delivery may be indicated by a deterioration of sonographic variables.  
 
 Prenatal corticosteroids for fetal lung maturation should be considered between 
24+0 and 34+0 weeks gestation, but may be given up until 38+0 weeks in cases of 
elective delivery by Caesarean section. Steroids should be administered in a timed 
manner. Multiple courses of steroids are not recommended.  
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 Decisions regarding the optimal timing of delivery need to be made on an individual 
basis and may require the involvement of an experienced obstetrician or fetal 
medicine specialist, in particular in severe, very preterm FGR.  
 
  MgSO4 for fetal neuroprotection should be administered if delivery is planned prior 
to 32 weeks gestation. 
 
 Mode of delivery needs to be discussed on an individual basis but Caesarean section 
is likely when AREDF UA Doppler waveforms are present, or in very preterm 
gestations.  
 
 If induction of labour is considered in women with abnormal UA Doppler, a 
continuous CTG should be performed once contractions have started, with a low 
threshold for Caesarean delivery.  
 
 Cord arterial and venous pH should be recorded for all FGR infants.  
 
 Histopathological examination of the placenta is strongly recommended in all cases 
where FGR is diagnosed prenatally or at birth to understand the underlying causes 
and guide management in a subsequent pregnancy (75).  
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SECTION 4.  MANAGEMENT PRINCIPLES for the HYPERTENSIVE DISORDERS OF 
PREGNANCY 
1. Chronic essential Hypertension 
 Use antihypertensives to maintain blood pressure in the range 110-
140 / 80-85 mmHg 
 Acceptable initial anti-hypertensives include labetalol, oxprenolol, 
methyldopa, nifedipine, diltiazem; prazosin and hydralazine are usually 
used as 2nd or 3rd line agents (76). 
 Home blood pressure monitoring is a very useful adjunct to clinic visits 
if available; about ¾ home BP devices are accurate (27) so we 
recommend checking device accuracy against a sphygmomanometer 
for each woman.  
 The key risks of chronic essential hypertension are  
o  super-imposed PE,  
o  fetal growth restriction,  
o  accelerated maternal hypertension 
 Therefore, monitor for developing pre-eclampsia using urinalysis at 
each visit along with clinical assessment, and blood tests (Hb, platelet 
count, liver transaminases, uric acid and creatinine) at 28 and 34 
weeks as a minimum. 
 Assess fetal wellbeing with ultrasound from 26 weeks’ gestation and 
thereafter at 2-4 weekly intervals if fetal biometry is normal and more 
frequently in the presence of suspected fetal growth restriction (see 
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above). 
 Indications for delivery are similar to those of pre-eclampsia (see 
below); if no such indication arises delivery at 39 weeks appears 
optimum (77) 
 
Notes:  
 The CHIPS trial (78) enrolled mostly chronic hypertensive women; targeting a 
DBP of 85mmHg was associated with reduced likelihood of developing 
accelerated maternal hypertension and no demonstrable adverse outcome 
for babies compared with targeting higher DBP. Therefore, current evidence 
supports controlling BP to these levels. 
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2. Chronic hypertension due to renal disease 
Management of this group is complex and beyond the scope of this 
document but is discussed in detail elsewhere (79, 80). General principles 
include: 
 Maternal and fetal outcomes are generally worse than the general 
population even when chronic kidney disease (CKD) is mild (81) 
 Control of maternal BP is important to pregnancy and long-term 
maternal renal outcome 
 Monitoring for superimposed pre-eclampsia and for adequate fetal 
growth is important 
 Early dialysis with an aggressive dialysis prescription of about 36 hrs. 
per week appears to convey the best outcome for those with 
progressive renal disease in pregnancy (82) 
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3. White-coat hypertension (Fig 3)  
 Where a diagnosis of white coat hypertension is confirmed, pregnant 
women can be managed with regular home blood pressure assessments and 
antihypertensives can be avoided, at least up to office blood pressure levels 
of 160/110 mmHg. 
 There are limited studies on the outcome of these pregnancies but it 
appears that up to half will develop true gestational hypertension or pre-
eclampsia(24); it is possible that the risk of pre-eclampsia is twice that of the 
normal pregnant population, though this needs to be confirmed.  The 
important messages around white coat hypertension are as follows: 
 it is reasonable to withhold antihypertensive therapy in this group,  
 blood pressure should continue to be monitored regularly at home,  
 Increased surveillance is required throughout pregnancy to detect the 
emergence of pre-eclampsia. 
o In areas where home blood pressure assessments are not available, 
maternal blood pressure should be checked regularly, preferably 
weekly, by a health care worker; this is probably best done by someone 
other than a doctor to reduce the likelihood of a white-coat effect.   
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4. Gestational Hypertension  
The key principles of management of gestational hypertension are: 
1. Control blood pressure to levels of 110-140 /85 mmHg, as above 
2. Monitor for development of pre-eclampsia 
3. Monitor fetal growth, especially if maternal uric acid is elevated 
4. Delivery can be delayed until 39+6 weeks provided blood pressure 
can be controlled, fetal monitoring is reassuring and pre-eclampsia 
has not developed. 
 
Notes 
 By definition, gestational hypertension is not a benign disorder as at least 
a quarter of such cases will progress to become pre-eclampsia (31) 
 There is no specific test or set of tests that allow prediction of which 
women with gestational hypertension will develop pre-eclampsia at the 
time they are diagnosed with gestational hypertension, although the risk 
is highest among those who present with gestational hypertension at <34 
weeks (32) 
 Women with gestational hypertension require assessment in hospital if 
they develop pre-eclampsia or severe hypertension >160/110 mmHg. 
 The optimum time for delivery remains uncertain for women with 
gestational hypertension and no features of pre-eclampsia. A large 
retrospective study concluded an optimum time of 38-39 weeks (83) but 
this will need to be clarified with future randomised trials. 
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5. Pre-eclampsia 
ANTE-NATAL 
ISSHP endorses the following key management points: 
1. Regardless of the hypertensive disorder of pregnancy, blood pressure 
requires urgent treatment in a monitored setting when ≥ 160/110 
mmHg; acceptable agents for this include oral nifedipine or intravenous 
labetalol or hydralazine. 
 
2. Regardless of the hypertensive disorder of pregnancy, we recommend 
that blood pressures consistently at or above 140/90 mmHg be treated 
aiming for a target diastolic blood pressure of 85 mmHg (and systolic 
blood pressure at least below 160 mmHg; some Units target 110 – 140 
mmHg) to reduce the likelihood of developing severe maternal 
hypertension and possibly other complications such as low platelets and 
elevated liver enzymes with symptoms. Antihypertensive drugs should 
be reduced or ceased if diastolic BP falls below 80mmHg Acceptable 
agents include oral methyldopa, labetalol, oxprenolol, nifedipine, with 
2nd or 3rd line agents hydralazine and prazosin. 
 
3. Women with pre-eclampsia should all be assessed in hospital when first 
diagnosed; thereafter some may be managed as outpatients once it is 
established that their condition is stable and they can be relied upon to 
report problems and monitor their blood pressure.  
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4. Women with pre-eclampsia who have proteinuria and severe hypertension, or 
hypertension with neurological signs or symptoms, should receive MgSO4 for 
convulsion prophylaxis. 
 
5. Plasma volume expansion is not recommended routinely in women with pre-
eclampsia 
 
6. Fetal monitoring in pre-eclampsia should include assessment of fetal biometry, 
amniotic fluid (AFI) and umbilical artery Doppler with ultrasound at first 
diagnosis and thereafter at 2 weekly intervals if the initial assessment was 
normal and more frequent AFI and Doppler in the presence of fetal growth 
restriction.  
 
7. Maternal monitoring in pre-eclampsia should include: BP monitoring, repeated 
assessments for proteinuria if not already present, clinical assessment 
including  clonus, and twice weekly blood tests for Hb, platelet count, liver 
transaminases, creatinine and uric acid. Evaluation should be performed at 
least twice weekly (and again in response to a change in clinical status) in most 
women with pre-eclampsia 
 
8. There should be no attempt to diagnose ‘mild’ vs. ‘severe’ pre-
eclampsia clinically as all cases may become emergencies, often rapidly. 
 Women with pre-eclampsia should be delivered if they have reached 37 
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weeks’ gestation or they develop any of the following: repeated 
episodes of severe hypertension despite maintenance treatment with 
three classes of antihypertensive agents; progressive 
thrombocytopenia; progressively abnormal renal or liver enzyme tests; 
pulmonary oedema; abnormal neurological features such as severe 
intractable headache, repeated visual scotomata, or convulsions; or 
non-reassuring fetal status. Neither the serum uric acid nor the level of 
proteinuria should be used as an indication for delivery. 
9. In low resource settings, all women with pre-eclampsia should receive 
MgSO4 for convulsion prophylaxis, typically a loading dose of 4g iv or 
10g intramuscular (imi), followed by 5g imi every 4 hours or an infusion 
of 1g/hr. until delivery and for at least 24 hrs. post-partum. 
 
10. In other centres women should receive MgSO4 if they have severe 
hypertension (>160/110 mmHg) and proteinuria or if there are 
premonitory signs of eclampsia such as severe headaches, repeated 
visual scotomata, or clonus.  
 
11. ISSHP does not advocate for any clinical distinction between mild and 
severe pre-eclampsia in usual clinical practice.  Instead, all cases of pre-
eclampsia should be treated in the knowledge that the condition can 
change rapidly and that world-wide, this remains a major cause of 
maternal mortality. 
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a. Distinctions between early and late onset, and mild and severe 
pre-eclampsia, may be useful for research purposes (3).  
However, for clinical purposes, the condition should be 
considered as one that is at any time capable of being severe 
and life-threatening for mother and baby (84). 
b. There are clinical findings that warrant closer attention; 
examples include ongoing or recurring severe headaches, visual 
scotomata, nausea/vomiting, epigastric pain, oliguria and severe 
hypertension as well as progressive derangements in laboratory 
tests such as rising creatinine or liver transaminases or falling 
platelet count, or failure of fetal growth or abnormal Doppler 
findings. These women should be followed in a centre with 
maternal high dependency or intensive care unit capacity for 
mother and baby.  
12. Delivery should be effected depending on gestational age and maternal 
and fetal status, as follows: 
a. Women with onset of pre-eclampsia at ≥37 weeks’ gestation should 
be delivered 
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b. Women with onset of pre-eclampsia between 34 and 37 weeks’ 
gestation should be managed with an expectant conservative 
approach, as below. 
c. Women with onset of pre-eclampsia at <34 weeks’ gestation 
should be managed with a conservative (expectant) approach at 
a centre with Maternal and Fetal Medicine expertise. 
d. Women with pre-eclampsia with a fetus at the limits of viability 
(generally before 24 weeks gestation) should be counselled that 
termination of pregnancy may be required.    
e. Delivery is necessary when one or more of the following 
indications emerge: 
i. Inability to control maternal blood pressure despite using 
3 or more classes of antihypertensives in appropriate 
doses. 
ii. Maternal pulse oximetry <90%  
iii. Progressive deterioration in liver function, creatinine, 
haemolysis or platelet count 
iv. Ongoing neurological features such as severe intractable 
headache, repeated visual scotomata, or eclampsia 
v. Placental abruption 
vi. Reversed end-diastolic flow in the umbilical artery 
Doppler velocimetry, a non-reassuring CTG, or stillbirth. 
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Notes: 
 The level of blood pressure itself is not a reliable way to stratify immediate 
risk in pre-eclampsia because some women may develop serious organ 
dysfunction such as renal impairment or neurological complications at 
relatively mild levels of hypertension. Hence, decisions to admit and monitor 
should be based upon having developed pre-eclampsia regardless of the initial 
BP levels. 
 
 Blood pressures at or above 160/110 mmHg are thought to be surrogate 
markers for the risk of stroke, as well as a reflection of increased severity of 
the overall condition of pre-eclampsia (85). In the follow-up of women in the 
CHIPS trial, the development of severe hypertension was associated with 
significantly greater likelihood of adverse outcomes for both the baby (i.e., 
low birth weight, prematurity, death and morbidity requiring neonatal unit 
care) and the mother (i.e., thrombocytopenia, abnormal liver enzymes with 
symptoms and longer hospital stay). Among women who were managed at 
the higher blood pressure target (of ‘less tight’ control), severe hypertension 
was also associated with significantly more serious maternal 
complications(85)  
 
 There is no universal agreement in clinical practice guidelines as to what 
blood pressure level should be maintained when antihypertensives are 
instituted for non-urgent indications in pregnancy. However, all guidelines 
were published prior to publication of the CHIPS Trial results(78). The 
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Canadian guidelines recommend 130-155/90-105 mmHg in the absence of co-
morbid conditions(86), and the NICE guidelines recommend keeping BP below 
150 mmHg systolic and between 80-100 mmHg diastolic(87). The USA SMFM 
decided not to endorse the finding of the CHIPS trial (88). Yet, as pointed out 
editorially “To manage BP expectantly at <160/110 mm Hg but emergently at 
>160/110 mm Hg is logically inconsistent”(89). ISSHP endorses an approach 
that seeks to reduce the likelihood of developing severe maternal 
hypertension, namely commencing antihypertensives to treat any persistent 
non-severe hypertension, well before BPs of 160/110 mmHg are reached. This 
recommendation applies to all hypertensive disorders of pregnancy. CHIPS 
enrolled women with chronic (75%) or gestational (25%) hypertension, but 
superimposed pre-eclampsia developed in almost half of women, and they 
continued to receive the blood pressure treatment to which they were 
randomised for two subsequent weeks prior to delivery.  
 
 The target blood pressure for antihypertensive therapy in the ‘tight’ control 
arm of CHIPS was a diastolic blood pressure of 85 mmHg, and a systolic blood 
pressure <160mmHg.  
 
 Each unit should have a protocol (based on national or international 
recommendations) that documents their recommended target blood pressure 
and regular audit of associated pregnancy outcomes is recommended. 
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 There is clear evidence that  MgSO4 prevents eclampsia, approximately 
halving the rate; overall approximately 100 women need  MgSO4 to prevent 
one seizure(90).  MgSO4 is effective in women with pre-eclampsia but the 
costs are higher for treatment of the latter because seizures are less common. 
ISSHP recommends that, especially because the cost benefit is greatest, all 
pre-eclamptic women in LMICs should receive MgSO4. In highly specialised 
centres, and in high income settings where the costs of administering MgSO4 
are higher, selective use in women with pre-eclampsia is reasonable. In the 
landmark Magpie Trial, women with pre-eclampsia were given MgSO4 if they 
had  severe hypertension and at least 3+ of proteinuria, or slightly lower 
measurements (150/100 mmHg and least 2+ of proteinuria) in the presence of 
at least two signs or symptoms of “imminent eclampsia” (which was not 
defined but is taken to mean headache, visual symptoms, or clonus) (91). 
ISSHP recommends that each unit has a consistent policy concerning their use 
of MgSO4 that incorporates appropriate monitoring, recognition of the risks of  
MgSO4 infusions, and assessment of maternal and fetal outcomes. The dosing 
regimens used in the Eclampsia and Magpie trials should be used.  
 
 The duration of  MgSO4 use post-partum remains contentious; one recent 
study in Latin America found that women who had received at least 8g of  
MgSO4 before delivery had no additional benefit of continuing the magnesium 
for a further 24 hrs. post-partum (92). This approach needs to take into 
consideration the known incidence of eclampsia post-partum. As such, either 
approach is reasonable but until further studies confirm these findings in 
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other populations, we recommend continuing MgSO4 for 24 hrs. post-partum. 
Each Unit should develop their own protocols for post-partum magnesium. 
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INTRA-PARTUM 
 Oral anti-hypertensives should be given at the start of labour  
 Treat hypertension urgently with oral nifedipine or either iv 
labetalol or hydralazine if blood pressure rises > 160/110 mmHg 
 Total fluid intake should be limited to 60-80 ml/Hr. 
 
Notes: 
 Reduced gastrointestinal motility may decrease absorption of 
antihypertensives following oral administration. Therefore, intravenous (ivi) 
antihypertensives may be needed to control blood pressure, particularly if it 
becomes severe.  
 
 Fluid balance should aim for euvolemia as at all other times. Pre-eclamptic 
women have capillary leak (93)  but may have either reduced or increased 
cardiac output (94, 95) . To ensure euvolemia, insensible losses should be 
replaced (30ml/hr.) along with anticipated urinary losses (0.5-1ml/kg/kr.). We 
suggest not using more than 80-100 ml/hr. to avoid risks of pulmonary 
oedema. There is no rationale to ‘run dry’ a pre-eclamptic woman as she is 
already at risk of acute kidney injury. 
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POST-PARTUM 
 Monitor blood pressure at least 4-6 hourly during the day for at least 3 
days post-partum 
 Pre-eclampsia may develop de novo intra- or early post-partum (96); 
such cases should be managed as above and a careful assessment for 
retained products should be made; these cases often take longer to 
settle post-partum. 
 Monitor general well-being and neurological status as per pre-delivery; 
eclampsia may occur post-partum 
 Repeat Hb, Platelets, Creatinine, liver transaminases the day after 
delivery then 2nd daily until stable if any of these were abnormal before 
delivery  
 Anti-hypertensives should be restarted after delivery and tapered slowly 
only after days 3-6 postpartum unless blood pressure becomes very low 
(<110/70mmHg) or the woman becomes symptomatic in the meantime. 
 Most women can be discharged by day 5 post-partum, especially when 
they are able to monitor their blood pressure at home. 
 Avoid NSAIDs in women with pre-eclampsia if possible, especially in the 
setting of AKI, and use alternative pain relief 
 
Notes: 
 There is controversy as to whether NSAIDs are harmful or not in this setting. 
Certainly some women develop severe hypertension from NSAIDs (97) but 
other observational studies suggest the risk is small, if any(98, 99). NSAIDs are 
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very effective analgesics. Until prospective randomised trials are conducted 
on this issue, we recommend using alternative analgesia as a first choice for 
women who have pre-eclampsia. 
 
SHORT-TERM FOLLOW-UP 
 Women with pre-eclampsia should be reviewed within one week if still 
requiring anti-hypertensives at discharge from hospital. 
 All women should be reviewed 3 months post-partum by which time 
blood pressure, urinalysis, and all laboratory tests should have 
normalised. 
 Further investigation is required for persistent abnormalities, including 
a work-up for secondary causes of persistent severe hypertension or 
underlying renal disease with persistent proteinuria.  
 Assessment should also include a clinical check for depression, anxiety 
or PTSD symptoms (100) 
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LONG-TERM FOLLOW-UP 
All women with chronic hypertension, gestational hypertension or pre-
eclampsia require lifelong follow-up because of their increased cardiovascular 
risk. We recommend: 
 Advice to women with gestational hypertension or pre-eclampsia that 
they have increased risks of cardiovascular disease, death, stroke (33, 
101, 102), diabetes, venous thromboembolic disease (VTE) and CKD 
compared with women who have had normotensive pregnancies (103).  
 Advice to women with pre-eclampsia that they have approximately a 
15% risk for developing pre-eclampsia again and a further 15% risk for 
gestational hypertension in a future pregnancy (104, 105) and that they 
should receive low-dose aspirin in another pregnancy. 
 Advice to women with gestational hypertension that they have 
approximately a 4% risk for developing pre-eclampsia and a further 25% 
risk for gestational hypertension in a future pregnancy (104, 105).  
 Advice to women with gestational hypertension or pre-eclampsia that 
they have increased risks of SGA babies in another pregnancy even if 
pre-eclampsia does not recur.  
 Regular follow-up with a general practitioner to monitor BP and periodic 
measurement of fasting lipids and blood sugar. 
 Adopt healthy lifestyle with maintenance of ideal weight and regular 
aerobic exercise 
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 Notes 
 The long-term risks of pre-eclampsia, and gestational hypertension, are now 
well established, though some believe these risks are confined to those who 
remain hypertensive and behave as chronic hypertensives (106). 
 
 It is probable that in the long-term these women have some degree of 
underlying metabolic syndrome and higher blood pressure than women who 
did not have hypertensive pregnancies (107, 108) 
 
 The values we use to define ‘normal’ blood pressure are derived from older 
and often male populations; ongoing studies will define a new ‘normal’ range 
of blood pressure for young women who have not had pre-eclampsia, thereby 
permitting a reassessment of whether a woman who has had pre-eclampsia 
truly has normal blood pressure when followed up 6 months or more post-
partum.(109) 
 
 Even with an elevated lifetime risk of cardiovascular disease, young women 
may have low 10-year cardiovascular risk scores using well-established tools, 
and may be overlooked as being at high risk on that basis.  
 
 Ongoing clinical studies may provide more specific information on how best 
to manage formerly pre-eclamptic women.  
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SECTION 5. APPLICATION OF THESE ISSHP RECOMMENDATIONS TO LOW RESOURCE 
COUNTRIES 
 
General recommendations 
 The recommendations described in this document are for an ideal setting. In some 
instances, it may not be possible to adopt all of these recommendations.  Health 
systems in low and middle-income countries (LMICs) may have to consider the 
minimum required to reach as many women as possible.   
 
 It is recommended that there is ongoing review and update of national and facility 
clinical guidelines, pre-service educational material and in-service training materials to 
ensure that all documents reflect these ISSHP recommendations so as to improve 
outcomes for women and babies.  
 
 In circumstances where the documented goals of this guideline are not attainable in 
their entirety, physicians should work pragmatically towards them as far as the local 
resources allow. 
 
 It is the responsibility of managing physicians to advocate for the use of effective 
interventions whether they practice in well- or under-resourced settings. 
 
 The distances between community clinics and referral hospitals are often large and 
transport problems exist.  For this reason patients diagnosed with pre-eclampsia should 
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be referred as soon as possible to a centre with an appropriate level of care and 
managed as in-patients.   
 
 The effectiveness of referral systems is in many low- and middle-income countries is 
less than optimal and many rural areas are without centres that can provide basic 
obstetric and neonatal services. Women diagnosed with pre-eclampsia in such settings 
should be advised to re-locate immediately to areas with better health care services, 
especially where they have family members if possible. 
 
 Communities should put strategies in place for transport from clinics or primary 
healthcare centres to referral centres. 
 
 All health care facilities should regularly review and update facility and community 
health worker referral pathways for women with pre-eclampsia. 
 
 All women with a hypertensive disorder of pregnancy require delivery in a centre that 
provides emergency obstetric and neonatal care, while women with maternal 
complications require delivery in a centre capable of providing maternal critical care. 
Those with pregnancies at the limit of viability require the highest available level of 
neonatal support. 
 
 Antihypertensive agents for treatment of moderate and severe hypertension and 
MgSO4 to prevent or treat eclampsia must be available at community level 
centres and clinics so that patients can be stabilised and referred safely. 
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 Women with pre-eclampsia in LMICs may have a limited comprehension of the 
nature and risks of the disease.  A South African study showed that a structured 
information sheet (in addition to verbal counselling by a physician) improved 
patients’ understanding and knowledge in a limited way but did not alleviate 
their anxiety (110).  Better understanding of the disease will lead to greater 
acceptance of advantageous treatment options and prime the patient for life-
long care of her health. 
 
 A key issue is the supply of MgSO4 which is rarely in stock; there are challenges with out 
of stock, challenges with the distribution system, the drug often being stuck at district 
level and then sitting there without getting to the health care facility. Priority should be 
given to provision of such stock. 
 
Antenatal Care 
The 2016 WHO guidelines on routine antenatal care (ANC) 
(http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-
positive-pregnancy-experience/en/) recommends several health systems interventions to 
increase use of antenatal services and improve the quality of care delivered. 
Recommendations include:  
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 Midwife-led continuity of care throughout the antenatal, intra-partum, and 
postnatal periods; 
 A minimum of 8 antenatal care contacts; 
 Women-held case notes;  
 Promotion of health-related behaviours and distribution of nutrition 
supplements;  
 Recruitment and retention of health workers in rural and remote areas (where 
one out of 20 people do not have access to essential health services); and 
 Community mobilisation to improve communication and support to pregnant 
women. 
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Prevention of hypertensive disorders in pregnancy 
 Prophylactic use of aspirin - use low dose aspirin for women with: 
o one or more of the major risk factors for pre-eclampsia  
 (Prior pre-eclampsia, Chronic hypertension, Pre-gestational 
diabetes, Maternal BMI >30, chronic kidney disease, Anti-
phospholipid syndrome) 
o or two or more of minor risk factors  
 (advanced maternal age, family history of pre-eclampsia, 
short duration of sexual relationship ( < 6 months) prior to 
the pregnancy, primiparity, primipaternity – both changed 
paternity and an interval greater than 5 years  have been 
associated with an increased risk for pre-eclampsia, 
connective tissue disorders). 
 preferably starting before 16 weeks’ gestation, until 37 weeks, using 100-150mg 
daily 
Calcium supplements 1200mg daily if dietary calcium intake is low in the local 
population   
 
Notes  
 Knowledge of prophylactic use of aspirin, and calcium where dietary intake is low, is very 
poor in district and health centres, even among doctors (Landscape analyses in Nigeria 
and Bangladesh – Ending Eclampsia - Population Council www.endingeclampsia.org).  
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 The main challenge is to identify women at risk of developing pre-eclampsia to receive 
aspirin and calcium supplementation before 16 weeks. Women in LMIC do not usually 
seek care much before 20 weeks. Therefore, community based messaging and education 
is required. 
 
 There is a need to ensure time and counselling skills in order that women take aspirin 
and calcium: 
- Confirm aspirin and calcium dosing and timing as per these international 
recommendations  
- Ensure aspirin prophylaxis is included in all national guidelines and protocols 
- Consider group based counselling and task shifting so that lower level health 
care workers can provide aspirin and calcium to women in areas where there 
is known calcium deficiency or a high prevalence of pre-eclampsia and for 
women with risk factors for pre-eclampsia as above.  
 
 Antiphospholipid antibody syndrome is not commonly diagnosed in LMIC or routinely 
seen as a risk factor; in any case enoxaparin is not widely available.  
 
 Health managers and facilities must estimate the expected number of pregnancies per 
annum and budget and procure aspirin and calcium in a timely manner to prevent stock-
outs and thereby ensure women benefit from these simple preventative measures.   
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Early detection and diagnosis  
 Aim to test the blood pressure and proteinuria at every visit.   
 In many contexts (due to frequent stock outs) urine can only be tested for protein 
if BP is raised and/or women present with symptoms such as headache, visual 
disturbance, epigastric pain. 
 For proteinuria the use of visual dipstick testing according to the manufacturer’s 
specification is acceptable. 
 Each ANC unit should have as a minimum a dedicated sphygmomanometer and 
urine dipsticks for detecting proteinuria.  
 Health care providers must be trained on how to measure blood pressure 
correctly using the appropriate technique  
Laboratory tests to rule out end-organ complications of pre-eclampsia are often not 
available at primary or even secondary level health facilities. Diagnosis will need to be 
made initially on the basis of B, symptoms and proteinuria until transfer to a tertiary 
facility. 
 
Notes:  
 Clear protocols are required in each unit, utilising the ISSHP recommendations for 
diagnosis and management 
 Confusion remains on definitions of hypertension and knowledge gaps persist across 
providers at both secondary and primary facilities, including when to initiate anti-
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hypertensives. These ISSHP recommendations should be publicised across low and 
middle income countries as the standards to be sought. 
 
 In LMIC settings home blood pressure monitoring is unlikely.  Women should be 
encouraged to attend for a minimum of eight ANC visits, attend more frequently if they 
develop warning symptoms or signs of pre-eclampsia or blood pressure was raised on 
prior visits. They must ‘know their blood pressure numbers’ and understand the 
importance of knowing what their BP should be, both before and after delivery. This 
requires ongoing education aiming towards women understanding the significance of 
having a raised BP. 
 
 In LMIC settings visual dipstick for proteinuria is used, not automated measurement. 
Often due to resource constraints, dipstick is only done if blood pressure is raised (above 
140/90mmHg). It is important for local groups to lobby for consistent supply. 
 
 The gold standard continues to be the 24-hr. urine protein measurement in LMIC. 
Quantifying with spot urine protein/creatinine ratio is rarely available but efforts should 
be made to ensure urine creatinine measurement is available thereby enabling spot P/Cr 
to be done. This should be a priority given the challenges and potentially dangerous time 
delays inherent in doing 24 hr. urine collections. Though it is unlikely to be done at 
primary health care level, health providers should work to ensure this is available in the 
tertiary hospital setting. 
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 Women in LMICs are usually referred to tertiary hospitals to receive all tests. 
However, many women do not go due to costs related to transport and to 
treatment. A signs and symptoms-based model (miniPIERS) is available to identify 
women at low risk of complications, and this should be explored for use at 
primary and secondary care levels.  
 
Fetal monitoring  
In some LMICs in tertiary facilities first and mid-trimester ultrasound, fetal biometry, 
amniotic fluid volume and fetal Doppler studies take place.  
 
Fundal height measurements may also take place every 2 weeks.  
 
However, the recent WHO ANC guidelines suggest that the following should not be 
continued due to insufficient evidence:  
 
- Routine daily fetal movement counting  
- Symphysis-fundal height measurement  
- Routine antenatal cardiotocography  
- Although recommended before 24 weeks, ultrasound should only be performed 
where capacity exists; Units should consider costs and maintenance of ultrasound 
equipment over the cost of ensuring sphygmomanometers are widely available to 
measure blood pressure, which can provide greater recognition of women with pre-
eclampsia.    
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Management of hypertensive disorders of pregnancy  
 Aim to maintain blood pressure 110-140 /85 mmHg  
o Typically Methyldopa and Nifedipine are used and both are acceptable. 
 Women with pre-eclampsia should all be assessed in hospital when first 
diagnosed; thereafter some may be managed as outpatients once it is established 
that their condition is stable and they can be relied upon to report problems and 
monitor their blood pressure 
 Laboratory tests are not always available at primary or even secondary level 
health facilities; when transfer to a higher level of care is not available, clinical 
decisions must be made using BP measures, fundal height assessment, symptoms, 
and urine dipstick testing when available.  
 At first referral level antihypertensive therapy and magnesium sulphate should be 
adjusted or continued as appropriate and women should be triaged for 
appropriate referral to tertiary-level care, including those eligible for expectant 
care and those at high risk of, or with severe maternal morbidity.  
 One protocol for treatment of acute severe hypertension is described in Figure 1; 
others may be developed by individual Units as desired.  
 Treatment and prevention of eclampsia is achieved ideally with the protocol of 
intravenous magnesium (Fig 2) which is that used in the MAGPIE trial; when this is 
not possible the ‘Pritchard regimen’ (also used in the MAGPIE trial) can be used as 
follows: 
o 4gram is administered as an intravenous dose and 5gram in one buttock and 
another 5gram in the other buttock. These together constitute the loading dose 
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(14grams). Thereafter, 5grams is administered every 4 hours for 24 hr. in 
alternate buttocks as maintenance dose. 
 At gestational age less than 34 weeks repeatedly weigh the relative benefits and 
risks of continuation of pregnancy against progression of maternal disease, using 
the recommendations  for timing of delivery in this document, viz. : 
o repeated episodes of severe hypertension despite maintenance treatment with 
three classes of antihypertensive agents;  
o progressive thrombocytopenia;  
o progressively abnormal renal or liver enzyme tests;  
o pulmonary oedema;  
o abnormal neurological features such as severe intractable headache, repeated 
visual scotomata, or convulsions;  
o Non-reassuring fetal status. 
 Prenatal corticosteroids for fetal lung maturation should be given between 24+0 
and 34+0 weeks gestation, but may be given up until 38+0 weeks in cases of 
elective delivery by Caesarean section; multiple steroid courses are not 
recommended. 
 
Notes:  
 Task shifting guidelines for both MgSO4 and antihypertensive treatment should be 
available in each Unit so that lower level providers can initiate treatment with a loading 
dose and refer. 
o  Task shifting policies vary on whether lower level providers can prescribe 
antihypertensives to keep blood pressure in the range 110-140 / 85 mmHg.  A 
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change in practice should be explored so that asymptomatic women without 
proteinuria or other evidence of pre-eclampsia could receive antihypertensives from 
lower level providers. 
o Task-shifting policies may only allow administration of intramuscular MgSO4. In such 
cases a woman should receive a loading dose of IM 5mgs MgSO4 in each buttock and 
refer. It is better to initiate treatment with this dose than refer without any MgSO4. 
 
 Clear protocols are required in each unit, utilising these ISSHP recommendations 
 
 In LMIC, oxprenolol, diltiazem and prazosin are not readily available and are costly; 
methyldopa and nifedipine are more readily available and either can be used as a first 
line treatment. 
 
 Regular blood work up at 28 and 34 weeks may not happen if a woman is not near a 
tertiary facility. Ultrasound is also not always available. Mostly workers use serial fundal 
height check.  
 
 Ensure every health facility/unit has clear clinical protocols for MgSO4 use; this is a key 
education priority. One study demonstrated that use of MgSO4 for prevention and 
treatment of eclampsia varied widely and was largely inconsistent with current 
international guidelines.  
 
 There is often poor knowledge of how to monitor for MgSO4 toxicity; this is a key area 
for education; the protocols in Fig 2. can be used.  
81 
 
Chronic hypertension in pregnancy 
 In LMIC, oxprenolol, diltiazem and prazosin are not readily available and 
costly; methyldopa and nifedipine are more readily available and either 
can be used as a first line treatment. 
 
 Where resources are limited and the combination of chronic hypertension 
and obesity are prevalent, the recommended tests may be reduced to 
haemoglobin, platelet count, serum creatinine, urinalysis and appropriate 
quantification of urinary protein as baseline reference. 
 
 Community based blood pressure measurement and protein dipsticks 
should be made available for women at first point of care - either by 
community based health worker or at primary health care level living far 
from tertiary/hospitals facilities. 
 
- Task shifting policies vary on whether lower level providers can 
prescribe antihypertensives to keep blood pressure in the range 110-
140 / 85 mmHg.  A change in practice should be explored so that 
asymptomatic women with chronic hypertension without evidence of 
pre-eclampsia could receive antihypertensives from lower level 
providers on an outpatient basis. 
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Postnatal care  
 Blood pressure should be recorded shortly after birth and if normal again 
within 6 hours. 
o Postnatal blood pressure should be controlled as per ISSHP 
recommendations  
 In LMIC blood tests are usually done twice in the week after birth if 
abnormal before delivery. 
 All women should have BP recorded and defer discharge for at least 24 hours or 
until vital signs are normal and/or treated or referred. Any woman with an 
obstetric complication and /or newborn with complications should stay in the 
hospital until both are stable. 
 WHO recommendations include:  
o stay in the facility for at least 24 hours, 
o Check up within 48-72 hours of the birth and again at 7 – 14 days 
and at six weeks post-partum. A home visit within the first week is 
recommended for those who did not deliver in a health facility. 
  All women should be reminded of the danger signs of pre-eclampsia 
following birth including headaches, visual disturbances, nausea, 
vomiting, epigastric or hypochondrial pain, feeling faint or convulsions. 
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Notes: 
 Discharge and follow up should occur at tertiary facility; referral to a physician at 
hospital is advised if hypertensive or renal problems persist. Every woman should 
have details/ documents to provide to the primary health care (PHC) facility for 
close follow up. 
 
 It is important to counsel/provide education on postpartum contraception and 
family planning regarding limiting/spacing of next pregnancy. Family planning 
counselling should start in the ANC and be offered to each woman before she 
leaves the facility and again when advised to come back at six weeks for infant 
immunisation and family planning consultation.  Any family planning method that 
the woman wants to receive is acceptable if based on comprehensive counselling 
(and is available in the particular country setting). 
 
 In many LMIC women go home within 6 -24 hours after birth. This should be discouraged 
after a pre-eclamptic pregnancy. Even in busy units with heavy pressure on post-natal 
beds women with pre-eclampsia should not be discharged early. 
 
 It is an important opportunity at the time of discharge to reinforce the 
importance of early antenatal care in the next pregnancy due to risks of recurrent 
pre-eclampsia. 
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What do other guidelines say? 
ISSHP acknowledges the expertise and rigorous approach that has been undertaken 
in the development of several key guidelines including: 
 NICE 2010 (87) 
 SOMANZ 2014 (111)  
 Canadian 2014 (112) 
 ACOG 2013(113)  
 The key areas in which these guidelines differ are: 
1. the requirement for proteinuria in the diagnosis of pre-eclampsia (NICE) 
2. the level at which routine antihypertensive treatment of blood pressure is 
mandatory and the target blood pressure thereafter (although all were 
published before the CHIPS Trial results were available) 
3. when  MgSO4 should be administered 
 
Other guidelines include those of WHO 2011 and IMPAC 2016. 
Adopting the management recommendations of any of these guidelines is entirely 
justified though one aim of the ISSHP is to see a single set of flexible and regularly 
updated guidelines throughout the world so as to reduce confusion around diagnosis 
and management of women with hypertension in pregnancy.  
Importantly, ISSHP recommends that each unit has a specific policy as to 
management guidelines that are to be followed so that there is uniform practice 
within each unit. In addition, each unit should strive to record and evaluate their 
maternal and fetal outcomes to ensure that their policies and guidelines remain 
appropriate at all times. 
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Guideline Process 
 
The first author drafted the initial document and sought further input from all co-authors; 
these authors were chosen as being expert members of the ISSHP executive (authors 1-7) 
with additional authors who had expertise and experience in the management of pre-
eclampsia in low resource countries (authors 7-10). Relevant literature up to April 2017 was 
included with an emphasis on more recent publications; the document was revised again 
after the publication of the ASPRE trial in August 2017.The first version was circulated by 
email to all members in March 2017 and eight subsequent versions emanated following 
email discussions to achieve consensus amongst the group. The document was then sent to 
all members of ISSHP Council for further comment and those who responded are listed in 
the acknowledgements below. The final version was concluded on December 28th 2017 then 
amended after reviewers’ comments by March 1st 2018. 
 
There were no sources of funding for this manuscript. 
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Figure Legends 
 
Fig 1.  Management of severe Hypertension with oral Nifedipine and/or intravenous 
Hydralazine  
 
Fig 2.  One protocol for use of Magnesium Sulphate for eclampsia treatment or 
prophylaxis Check the concentration of Mg carefully to ensure a match with the 
doses below. Different countries may have different strength Mg concentrations.  
 
Fig 3. Clinical application of ABPM in early pregnancy to diagnose and manage 
white-coat hypertension. Hypertension is diagnosed if either systolic or 
diastolic BP is elevated, awake or sleep. ABPM = ambulatory blood pressure 
monitoring; GH = gestational hypertension;  PE = pre-eclampsia; HBPM = 
home blood pressure monitoring. ( from reference (114)) 
